Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lumos Pharma Inc
(NQ:
LUMO
)
2.795
UNCHANGED
Streaming Delayed Price
Updated: 3:58 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
154
Open
2.795
Bid (Size)
2.710 (1)
Ask (Size)
2.840 (1)
Prev. Close
2.795
Today's Range
2.795 - 2.795
52wk Range
2.410 - 4.550
Shares Outstanding
8,357,391
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
April 18, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Lumos Pharma Inc. (NASDAQ: LUMO) Receives Patent Notice for Improved Formulation of Lead Therapeutic Candidate
March 25, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Performance
YTD
-13.20%
-13.20%
1 Month
+0.18%
+0.18%
3 Month
+0.18%
+0.18%
6 Month
-29.95%
-29.95%
1 Year
-14.53%
-14.53%
More News
Read More
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
March 20, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma: Q4 Earnings Insights
March 07, 2024
Via
Benzinga
LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023
March 07, 2024
Via
InvestorPlace
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
March 07, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
February 26, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
February 05, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 7, 2024
March 07, 2024
Via
Benzinga
Earnings Preview: Lumos Pharma
March 06, 2024
Via
Benzinga
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
January 04, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
November 21, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
November 20, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Why Toast Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 08, 2023
Via
Benzinga
Why Is Biomarin & BridgeBio Pharma Rival Lumos Pharma Stock Trading Higher Today?
November 08, 2023
Via
Benzinga
Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday
November 08, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 08, 2023
Via
Benzinga
Why American Public Education Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
November 08, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
November 08, 2023
Via
InvestorPlace
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
November 07, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
November 07, 2023
Via
Benzinga
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
November 07, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 30, 2023
Via
Benzinga
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
September 26, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
September 14, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.